FibroGen, Inc. is a biopharmaceutical company that finds, develops, and sells treatments for serious medical conditions. Their primary products include Roxadustat, an oral inhibitor of hypoxia inducible factor prolyl hydroxylases and Pamrevlumab, a human monoclonal antibody that inhibits connective tissue growth factor activity. The company has partnerships with Astellas Pharma Inc. and AstraZeneca AB and is situated in San Francisco, California.